These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36582107)

  • 41. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer.
    Johansen K; Woodhouse NJ; Odugbesan O
    J Nucl Med; 1991 Feb; 32(2):252-4. PubMed ID: 1992028
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant Human Thyrotropin Worsens Renal Cortical Perfusion and Renal Function in Patients After Total Thyroidectomy Due to Differentiated Thyroid Cancer.
    Saracyn M; Lubas A; Bober B; Kowalski Ł; Kapusta W; Niemczyk S; Wartofsky L; Kamiński G
    Thyroid; 2020 May; 30(5):653-660. PubMed ID: 31964314
    [No Abstract]   [Full Text] [Related]  

  • 43. RADIOISOTOPE DIAGNOSTIC ALGORITHM FOR THE RELAPSE AND METASTASES DETECTION IN THE IODINE-NEGATIVE DIFFERENTIATED THYROID CANCER.
    Solodyannikova OI; Kmetyuk YV; Danilenko VV; Sukach GG
    Probl Radiac Med Radiobiol; 2020 Dec; 25():579-591. PubMed ID: 33361863
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer.
    Ceccarelli C; Battisti P; Gasperi M; Fantuzzi E; Pacini F; Gualdrini G; Pierantoni MC; Luciani A; Djokich D; Pinchera A
    J Nucl Med; 1999 Oct; 40(10):1716-21. PubMed ID: 10520714
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinoma.
    Courbon F; Zerdoud S; Bastie D; Archambaud F; Hoff M; Eche N; Berry I; Caron P
    Thyroid; 2006 Oct; 16(10):1025-31. PubMed ID: 17042689
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 124I PET Assessment of Response of Bone Metastases to Initial Radioiodine Treatment of Differentiated Thyroid Cancer.
    Jentzen W; Verschure F; van Zon A; van de Kolk R; Wierts R; Schmitz J; Bockisch A; Binse I
    J Nucl Med; 2016 Oct; 57(10):1499-1504. PubMed ID: 27199362
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value and optimal threshold of first thyroglobulin in low/intermediate risk DTC.
    Zakavi SR; Ayati N; Zare S; Ayati A; Sadri K; Fekri N; Abbasi B; Shafiei S
    Q J Nucl Med Mol Imaging; 2021 Mar; 65(1):64-71. PubMed ID: 30916533
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma.
    Reiners C; Biko J; Haenscheid H; Hebestreit H; Kirinjuk S; Baranowski O; Marlowe RJ; Demidchik E; Drozd V; Demidchik Y
    J Clin Endocrinol Metab; 2013 Jul; 98(7):3039-48. PubMed ID: 23616148
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The influence of thyroid hormone medication on intra-therapeutic half-life of
    Happel C; Kranert WT; Bockisch B; Sabet A; Grünwald F; Groener D
    Sci Rep; 2022 Aug; 12(1):13925. PubMed ID: 35978004
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
    Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
    Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radioprotective Effects of Amifostine, L-Carnitine and Vitamin E in Preventing Early Salivary Gland Injury due to Radioactive Iodine Treatment.
    Torun N; Muratli A; Serim BD; Ergulen A; Altun GD
    Curr Med Imaging Rev; 2019; 15(4):395-404. PubMed ID: 31989909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is thyroid stunning clinically relevant? A retrospective analysis of 208 patients.
    Etchebehere EC; Santos AO; Matos PS; Assumpção LV; Lima MC; Lima MC; Ward LS
    Arq Bras Endocrinol Metabol; 2014 Apr; 58(3):292-300. PubMed ID: 24863093
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer.
    Freudenberg LS; Jentzen W; Marlowe RJ; Koska WW; Luster M; Bockisch A
    Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):690-3. PubMed ID: 18058605
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.
    Campennì A; Amato E; Laudicella R; Alibrandi A; Cardile D; Pignata SA; Trimarchi F; Ruggeri RM; Auditore L; Baldari S
    Endocrine; 2019 Jul; 65(1):132-137. PubMed ID: 30875058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial.
    Bohuslavizki KH; Klutmann S; Jenicke L; Kröger S; Buchert R; Mester J; Clausen M
    Cancer Biother Radiopharm; 1999 Oct; 14(5):337-47. PubMed ID: 10850318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
    Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
    Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Calculation of Blood Dose in Patients Treated With 131I Using MIRD, Imaging, and Blood Sampling Methods.
    Piruzan E; Haghighatafshar M; Faghihi R; Entezarmahdi SM
    Medicine (Baltimore); 2016 Mar; 95(11):e3154. PubMed ID: 26986171
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
    Luster M; Lassmann M; Haenscheid H; Michalowski U; Incerti C; Reiners C
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3640-5. PubMed ID: 11061516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Radioiodine therapy of autonomously functioning thyroid nodules and Graves' disease].
    Guhlmann CA; Rendl J; Börner W
    Nuklearmedizin; 1995 Feb; 34(1):20-3. PubMed ID: 7724360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.